Crispr Therapeutics is expected to report a Q2 2026 loss of $1.10 per share on revenue of $7.11 million, with the stock currently trading at $47.53 against an average analyst target of $72.00.
Investors are primarily focused on the commercial ramp of Casgevy, the company's first-ever approved gene therapy for sickle cell disease and beta thalassemia.
After a slow initial launch, the focus has shifted to patient initiation counts, which exceeded 500 globally as of the first quarter. Analysts are watching for signs that expanding insurance coverage in the U.S. and new pricing agreements in Europe, particularly Germany, are accelerating revenue realization for the therapy's high-cost, complex treatment cycle.